Overview

A Study of RPL554 in Patients With Cystic Fibrosis

Status:
Completed
Trial end date:
2017-11-03
Target enrollment:
Participant gender:
Summary
This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.
Phase:
Phase 2
Details
Lead Sponsor:
Verona Pharma plc
Collaborator:
Cystic Fibrosis Trust